Publication:
Skin-on-a-chip technologies towards clinical translation and commercialization

dc.contributor.coauthorAbacı, Hasan Erbil
dc.contributor.kuauthorTarar, Ceren
dc.contributor.kuauthorDabbagh, Sajjad Rahmani
dc.contributor.kuauthorDilmani, Asghari Sara
dc.contributor.kuauthorSokullu, Emel
dc.contributor.kuauthorTaşoğlu, Savaş
dc.contributor.researchcenterKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.researchcenterKUAR (KU Arçelik Research Center for Creative Industries)
dc.contributor.schoolcollegeinstituteGraduate School of Sciences and Engineering
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.date.accessioned2024-12-29T09:36:30Z
dc.date.issued2024
dc.description.abstractSkin is the largest organ of the human body which plays a critical role in thermoregulation, metabolism (e.g. synthesis of vitamin D), and protection of other organs from environmental threats, such as infections, microorganisms, ultraviolet radiation, and physical damage. Even though skin diseases are considered to be less fatal, the ubiquity of skin diseases and irritation caused by them highlights the importance of skin studies. Furthermore, skin is a promising means for transdermal drug delivery, which requires a thorough understanding of human skin structure. Current animal and in vitro two/three-dimensional skin models provide a platform for disease studies and drug testing, whereas they face challenges in the complete recapitulation of the dynamic and complex structure of actual skin tissue. One of the most effective methods for testing pharmaceuticals and modeling skin diseases are skin-on-a-chip (SoC) platforms. SoC technologies provide a non-invasive approach for examining 3D skin layers and artificially creating disease models in order to develop diagnostic or therapeutic methods. In addition, SoC models enable dynamic perfusion of culture medium with nutrients and facilitate the continuous removal of cellular waste to further mimic the in vivo condition. Here, the article reviews the most recent advances in the design and applications of SoC platforms for disease modeling as well as the analysis of drugs and cosmetics. By examining the contributions of different patents to the physiological relevance of skin models, the review underscores the significant shift towards more ethical and efficient alternatives to animal testing. Furthermore, it explores the market dynamics of in vitro skin models and organ-on-a-chip platforms, discussing the impact of legislative changes and market demand on the development and adoption of these advanced research tools. This article also identifies the existing obstacles that hinder the advancement of SoC platforms, proposing directions for future improvements, particularly focusing on the journey towards clinical adoption.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue4
dc.description.openaccesshybrid
dc.description.publisherscopeInternational
dc.description.sponsorsS T acknowledges Tubitak 2232 International Fellowship for Outstanding Researchers Award (118C391), Tubitak 1001 Research Grant (123S582, 123Z050), Alexander von Humboldt Research Fellowship for Experienced Researchers, Marie Sklodowska-Curie Individual Fellowship (101003361), and Royal Academy Newton-Katip Celebi Transforming Systems Through Partnership award (120N019) for financial support of this research. This work was partially supported by Science Academy's Young Scientist Awards Program (BAGEP), Outstanding Young Scientists Awards (GEBIP), and Bilim Kahramanlari Dernegi The Young Scientist Award. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the TUBITAK. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
dc.description.volume16
dc.identifier.doi10.1088/1758-5090/ad5f55
dc.identifier.eissn1758-5090
dc.identifier.issn1758-5082
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85198998968
dc.identifier.urihttps://doi.org/10.1088/1758-5090/ad5f55
dc.identifier.urihttps://hdl.handle.net/20.500.14288/22086
dc.identifier.wos1268221100001
dc.keywordsSkin-on-a-chip
dc.keywordsOrgan-on-a-chip
dc.keywordsSkin models
dc.keywordsDrug and cosmetics testing
dc.keywordsPatent analysis
dc.keywordsMarket analysis
dc.keywordsClinical translation
dc.languageen
dc.publisherIOP Publishing Ltd
dc.sourceBiofabrication
dc.subjectEngineering, biomedical
dc.subjectMaterials science, biomaterials
dc.titleSkin-on-a-chip technologies towards clinical translation and commercialization
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorIsmayilzada, Nilufar
local.contributor.kuauthorTarar, Ceren
local.contributor.kuauthorDabbagh, Sajjad Rahmani
local.contributor.kuauthorTokyay, Begüm Kübra
local.contributor.kuauthorDilmani, Asghari Sara
local.contributor.kuauthorSokullu, Emel
local.contributor.kuauthorTaşoğlu, Savaş

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
IR04741.pdf
Size:
3.73 MB
Format:
Adobe Portable Document Format